| Literature DB >> 27770796 |
Aura Falco1, Yusibeska Ramos2, Esther Franco3, Alegría Guzmán3, Howard Takiff4.
Abstract
BACKGROUND: Klebsiella pneumoniae is a bacterial pathogen that has developed resistance to multiple antibiotics and is a major cause of nosocomial infections worldwide. Carbapenemase-producing Klebsiella pneumoniae have been isolated in many hospitals in Venezuela, but they have not been well-studied. The aim of this study was to characterize carbapenem-resistant Klebsiella pneumoniae isolates from the pediatric service of a hospital located in Anzoategui State, in the eastern part of Venezuela.Entities:
Keywords: Klebsiella pneumoniae; ST833; carbapenem; resistance
Mesh:
Substances:
Year: 2016 PMID: 27770796 PMCID: PMC5075218 DOI: 10.1186/s12879-016-1927-y
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Clinical characteristics of patients infected by carbapenem-resistant K. pneumoniae isolates from a Venezuelan Hospital
| No. (%) of isolates | |
|---|---|
| Characteristic | Total no. |
| Gender | |
| Female | 7 (36.9 %) |
| Male | 12 (63.1 %) |
| Age | |
| Newborn (0–6 days) | 14 (73.7 %) |
| Lower infant (1–12 months) | 2 (10.5 %) |
| Higher infant (1–2 years) | 2 (10.5 %) |
| School (5–10 years) | 1 (5.3 %) |
| Infection site | |
| Bloodstream | 15 (79 %) |
| Bronchial secretion | 2 (10.4 %) |
| Catheter | 1 (5.3 %) |
| Lesion secretion | 1 (5.3 %) |
| Hospitalization área | |
| Neonatal | 12 (63.2 %) |
| Internal medicine | 2 (10.5 %) |
| Intensive care | 2 (10.5 %) |
| Surgery | 3 (15.8 %) |
Antibiotic susceptibility profiles of carbapenem-resistant K. pneumoniae isolates from a Venezuelan Hospital
| Profile:Isolates | CM | AK | CIP | TE | TYG | % of isolates belonging profile |
|---|---|---|---|---|---|---|
| 1: ANZ2, ANZ4, ANZ6 | S | S | R | S | S | 15.8 |
| 2: ANZ8, ANZ11, ANZ12, ANZ13 | S | S | R | R | S | 21.0 |
| 3: ANZ10 | S | R | S | R | S | 5.3 |
| 4: ANZ1, ANZ3, ANZ19 | S | R | R | R | S | 15.8 |
| 5: ANZ5, ANZ7, ANZ9, ANZ14 | R | R | R | R | S | 21.0 |
| 6: ANZ16 | R | R | R | R | - | 5.3 |
| 7: ANZ17, ANZ18, ANZ21 | R | R | R | R | R | 15.8 |
All strains were resistant to imipenem, meropenem, and trimethoprim-sulfamethoxazole
CM chloramphenicol, AK amikacin, CIP Ciprofloxacin, TE tetracycline, TGC tigecycline, (−) no data
Fig. 1REP-PCR profiles of 19 isolates of bla VIM-2 and bla KPC-2-coharboring K. pneumoniae from a Public Venezuelan Hospital. Bands were visualized with ethidium bromide staining on a 1.0 % TBE agarose gel. M: Molecular Weight Marker 100 bp ladder (New England Biolabs®), line 1: ANZ1, line 2: ANZ2, line 3: ANZ3, line 4: ANZ4, line 5: ANZ5, line 6: ANZ6, line 7: ANZ7, line 8: ANZ8, line 9: ANZ9, line 10: ANZ10, line 11: ANZ11, line 12: ANZ12, line 13: ANZ13, line 14: ANZ14, line 16: ANZ16, line 17: ANZ17, line 18: ANZ18, line 19: ANZ19, line 21: ANZ21. The table to the right illustrates results from the bla KPC sequence analysis, MLST and sequence analysis of the nonconserved region of the Tn4401 element
Fig. 2Plasmidic DNA profile of 19 isolates from a Public Venezuelan Hospital. Bands were visualized with ethidium bromide staining on a 0.7 % TBE agarose gel. Line 1: 100 bp ladder (New England Biolabs®), line 2: Escherichia coli XL1-Blue (negative control), line 3: ANZ1, line 4: ANZ2, line 5: ANZ3, line 6: ANZ4, line 7: ANZ5, line 8: ANZ6, line 9: ANZ7, line 10: ANZ8, line 11: ANZ9, line 12: ANZ10, line 13: 100 bp ladder (New England Biolabs®), line 14: Escherichia coli XL1-Blue (negative control), line 15: ANZ11, line 16: ANZ12, line 17: ANZ13, line 18: ANZ14, line 19: ANZ16, line 20: ANZ17, line 21: ANZ18, line 22: ANZ19, line 23: ANZ21